Mangalam Drugs & Organics Share News - Latest Updates, Live News & More

Latest news about Mangalam Drugs & Organics

Mangalam Drugs & Organics defaults on ₹15.57 crore loans 5 days ago

Mangalam Drugs & Organics has defaulted on loans totalling ₹15.57 crore. The defaulted dues are owed to Bank of Maharashtra and Bank of Baroda. Repayments are overdue for more than 30 days across both lenders.

Mangalam Drugs schedules 53rd AGM for September 23, 2026 Sep 01, 2026

Mangalam Drugs Q1 Results: Net loss narrows 45% YoY to ₹755 lakh Aug 12, 2026

Mangalam Drugs and Organics: Secretarial Auditor M/s. Ragini Chokshi & Co. Resigns Effective August 4, 2026 Aug 06, 2026

Mangalam Drugs re-appoints Independent Director for second term Jun 18, 2026

More news about Mangalam Drugs & Organics

18Jun 26

Mangalam Drugs promoters declare no encumbrance in FY 2025-26

Promoters of Mangalam Drugs and Organics declared no new encumbrances on shares in FY 2025-26, complying with SEBI regulations. The filing confirms no direct or indirect charges beyond prior disclosures.

20May 26

Mangalam Drugs Seeks Votes for Director Re-appointment

Mangalam Drugs & Organics Limited has initiated a postal ballot process to secure shareholder approval for the re-appointment of Shri Praveen Saxena as an Independent Director for a five-year term. The remote e-voting facility is available from May 19, 2026, to June 17, 2026, for members registered as of the May 15, 2026 cut-off date. Shri Brij Mohan Maheshwari has been appointed as the Scrutinizer to oversee the voting process.

19May 26

Mangalam Drugs & Organics Posts ₹4,440 Lakh Consolidated Net Loss in FY26

Mangalam Drugs and Organics Limited reported a consolidated net loss of ₹4,440.00 lakh for the year ended March 31, 2026, reversing from a net profit of ₹672.07 lakh in the prior year, as consolidated revenue from operations declined sharply to ₹23,213.27 lakh from ₹31,757.60 lakh. The Board approved the results on May 14, 2026, and the audited financial results were subsequently published in Financial Express and Loksatta newspapers, with copies submitted to stock exchanges on May 15, 2026. On a standalone basis, the net loss stood at ₹4,381.42 lakh, while total consolidated assets declined to ₹31,496.93 lakh from ₹36,642.17 lakh.

06May 26

Mangalam Drugs & Organics Board Meeting Scheduled for May 14, 2026 to Consider FY26 Audited Financial Results

Mangalam Drugs & Organics has intimated stock exchanges of a board meeting to be held on May 14, 2026, at its Mumbai registered office, pursuant to Regulation 29 of SEBI (LODR) Regulations, 2015. The meeting will consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window for designated persons has been closed since April 1, 2026, and will remain shut until 48 hours after the financial results are declared. The intimation was signed by Managing Director Govardhan M. Dhoot on May 6, 2026.

17Apr 26

Mangalam Drugs Files Revised Disclosure on Company Secretary Resignation

Mangalam Drugs & Organics Limited submitted a revised regulatory disclosure regarding the resignation of Company Secretary & Compliance Officer Ms. Anuradha Pandey, effective March 29, 2026. The filing, submitted on April 17, 2026, addressed BSE's concerns about discrepancies in the earlier submission and acknowledged administrative oversight causing delayed compliance with SEBI (LODR) Regulations.

16Apr 26

Mangalam Drugs and Organics Limited Reports Subsequent Default on Bank Loan Accounts Worth ₹1558 Lacs

Mangalam Drugs and Organics Limited disclosed subsequent defaults on bank loan accounts totaling ₹1558.05 lacs as of April 15, 2026. The defaults involve cash credit facilities with Bank of Maharashtra (₹951.97 lacs) and Bank of Baroda (₹606.08 lacs), with default periods starting in October 2025. The company made the disclosure under SEBI regulations and indicated arrangements are being made to clear the overdue amounts.

10Apr 26

Mangalam Drugs Promoter Group Releases Pledged Shares Worth 1,500 Units

Shree Kishoriju Trading and Investments Private Limited released 1,500 pledged shares of Mangalam Drugs & Organics Limited on 06/02/2026, as disclosed to stock exchanges on 10/04/2026. The shares were previously encumbered with M/s Badjate Stock Broking Private Ltd as security for debt. Post-release, the promoter's total holding remains at 5,07,099 shares (3.20% of share capital) with no encumbered shares remaining.

07Apr 26

Mangalam Drugs & Organics Limited Submits Compliance Certificate for Quarter Ended March 31, 2026

Mangalam Drugs & Organics Limited submitted its compliance certificate under SEBI Depositories Regulations for the quarter ended March 31, 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of securities dematerialisation processes during January-March 2026. The company communicated this regulatory compliance to BSE and NSE on April 06, 2026, demonstrating adherence to mandatory reporting requirements.

26Mar 26

Mangalam Drugs Board Approves Company Secretary Changes in March 26 Meeting

Mangalam Drugs & Organics Limited concluded its board meeting on March 26, 2026, approving key personnel changes in the Company Secretary position. The board accepted Ms. Anuradha Pandey's resignation effective March 29, 2026, and appointed Ms. Shweta Patel as the new Company Secretary & Compliance Officer from April 1, 2026.

18Mar 26

Mangalam Drugs Maintains Bank Loan Defaults at ₹1,585.29 Lakh in March Update

Mangalam Drugs and Organics Limited disclosed its latest bank loan default status showing no change from previous month, with total overdue amounts remaining at ₹1,585.29 lakh across Bank of Maharashtra and Bank of Baroda. The defaults have persisted for five months since October 2025, with management continuing efforts to resolve the outstanding obligations.

18Mar 26

Mangalam Drugs & Organics Promoter Releases Pledged Shares Worth 0.56% Stake

Mangalam Drugs & Organics Limited disclosed the release of 89,000 pledged shares by promoter Aditya Ramniwas Dhoot on March 16, 2026, representing 0.56% of total share capital. The shares were released from pledge to M/s Famy care Private Ltd, where they had been held as security for debt. Dhoot continues to maintain his 0.56% stake with 89,225 total shares in the pharmaceutical company.

18Mar 26

Mangalam Drugs Promoter Releases 1,73,000 Pledged Shares Worth 1.09% Stake

Shree Rasbihari Trading and Investments Private Limited released 1,73,000 pledged shares of Mangalam Drugs & Organics Limited on March 18, 2026, representing 1.09% of total share capital. The shares were previously encumbered as security for debt with M/s Famycare Private Ltd. The promoter maintains its overall 6.20% stake (9,82,563 shares) with no remaining pledged shares, as disclosed under SEBI takeover regulations to BSE and NSE.

06Feb 26

Mangalam Drugs & Organics Board Meeting Outcome: Director Changes and CFO Appointment

Mangalam Drugs & Organics Limited conducted a board meeting on February 6, 2026, approving significant leadership changes. The company accepted the resignation of Independent Director Shri Rukmesh P. Dhandhania effective January 16, 2026, appointed Mr. Jeevan Mukund Dalvi as Chief Financial Officer with over two decades of finance experience, and approved Dr. Praveen Saxena's re-appointment as Independent Director for a second five-year term subject to shareholder approval.

15Jan 26

Mangalam Drugs & Organics Reports Q3 FY26 Loss of ₹983.55 Lakhs, Key Resignations

Mangalam Drugs & Organics Limited announced Q3 FY26 results showing consolidated net loss of ₹983.55 lakhs compared to profit of ₹128.68 lakhs in Q3 FY25, with total income declining 34.08% to ₹5,848.75 lakhs. The board meeting on January 15, 2026, also accepted resignations of CFO Ajay Samant (effective January 31, 2026) due to health reasons and Company Secretary Anuradha Pandey (effective March 29, 2026) for career advancement.

07Jan 26

Mangalam Drugs & Organics Clarifies No Material Information Behind Recent Price Movement

Mangalam Drugs & Organics Limited responded to BSE surveillance regarding recent stock price movements, clarifying no material undisclosed information exists. The company attributed price fluctuations to market sentiment and confirmed timely disclosure of all material information as per regulatory requirements.

24Dec 25

Mangalam Drugs & Organics CFO Ajay Samant Resigns Upon Reaching Retirement Age

Mangalam Drugs & Organics Limited announced the resignation of CFO Mr. Ajay Samant, effective March 31, 2025, due to reaching retirement age per company guidelines. The resignation was tendered on March 28, 2025, and approved by the Board on March 29, 2025. The company initially missed disclosing the resignation reason but has now provided complete information to comply with SEBI LODR Regulations.

25Nov 25

Mangalam Drugs Secures Rs. 15 Crore Export Order for Anti-Malarial API

Mangalam Drugs & Organics Limited (MDOL) has received a repeat export order for Anti-Malarial Active Pharmaceutical Ingredient (API) from an international client. The order is valued at approximately Rs. 15 Crore and will be executed over the next 2-4 months. This development is expected to strengthen MDOL's position in the global pharmaceutical market, contribute to its growth trajectory, and enhance revenue visibility in the near term.

18Nov 25

Mangalam Drugs & Organics Defaults on Bank Loans Totaling Rs 765.19 Lacs

Mangalam Drugs & Organics Limited has defaulted on loan obligations totaling Rs 765.19 lacs to Bank of Maharashtra (Rs 414.93 lacs) and Bank of Baroda (Rs 350.26 lacs). The defaults began in October 2025 and have exceeded 30 days. The company attributes the financial stress to discontinued US Aid funding and reduced orders for TB, HIV, and Malaria treatments. Mangalam has requested loan restructuring and plans to submit a restructuring plan by mid-December 2025.

13Nov 25

Mangalam Drugs and Organics Reschedules Board Meeting to November 20, 2025

Mangalam Drugs & Organics Limited has postponed its Board of Directors meeting from November 13 to November 20, 2025. The meeting agenda includes approving Q3 2025 financial results and acknowledging the CFO's resignation. A trading window closure is in effect from October 1, 2025, until 48 hours after the results announcement.

15Oct 25

Mangalam Drugs and Organics Receives NCLT Approval for Merger Scheme

Mangalam Drugs & Organics Limited (MDOL) received an NCLT order admitting a petition for a merger scheme involving Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited. The petition was presented on September 23, 2025, with a final hearing scheduled for December 16, 2025. NCLT has directed notices to be issued to various statutory authorities, giving them 30 days to submit representations. MDOL will keep stock exchanges informed of further developments.

06Oct 25

Manglam Group Launches ₹100 Crore Redevelopment Project in Mumbai's Borivali

Manglam Group has launched its first redevelopment project in Mumbai, Manglam Rajanigandha, in Borivali (West) with a ₹100 crore investment. The project, expected to generate ₹150 crore in revenue, will offer 80 two-bedroom apartments across 80,000 sq. ft. Half of the units will be allocated to existing tenants. The development includes amenities like landscaped green zones, a fitness center, and a jogging track. Homeowners will receive lifetime membership at the Mandapeshwar Civic Federation Gymkhana. The project is set for completion in June 2026.

06Sept 25

Mangalam Drugs Shares Pledged by Shree Kishoriju Trading for Debt Security

Shree Kishoriju Trading and Investment Private Limited has pledged 877,000 shares (5.54%) of Mangalam Drugs & Organics Limited to Badjate Stock Broking Private Limited. This increases Shree Kishoriju's total encumbered holdings to 1,098,515 shares, representing 6.94% of the company's share capital. Director Radhika Ajay Dhoot disclosed this information to stock exchanges in compliance with regulations.

14Aug 25

Mangalam Drugs & Organics' Merger Scheme Receives Strong Backing from Unsecured Creditors

Mangalam Drugs & Organics Limited's proposed merger scheme gained overwhelming support from unsecured creditors at a Tribunal Convened Meeting. The scheme, involving the absorption of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited, received 98.46% approval in value terms. Out of 80 eligible creditors, 36 participated, with 37 voting in favor and 1 against. The Board of Directors is now authorized to proceed with implementing the merger, subject to regulatory approvals.

Mangalam Drugs & Organics

34.26

+2.29

(+7.16%)

1 Year Returns:-54.40%

Industry Peers

Sun Pharmaceutical

1,837.30

(-1.61%)

Divis Laboratories

9,375.00

(+0.56%)

Torrent Pharmaceuticals

4,840.00

(-0.72%)

Zydus Life Science

1,160.00

(+2.19%)

Cipla

1,394.50

(+1.32%)

Laurus Labs

1,954.00

(+0.30%)

Aurobindo Pharma

1,734.00

(+2.60%)

Dr Reddys Laboratories

1,185.00

(+0.85%)

Lupin

2,083.00

(-0.72%)

Mankind Pharma

2,300.70

(+0.03%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104